

October 26, 2025

To
The Listing Department,
National Stock Exchange of India Limited,
Exchange Plaza, Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051

Scrip Symbol: COHANCE

To
The Department of Corporate Services,
BSE Limited
25th floor, P. J. Towers,
Dalal Street, Mumbai – 400 001

Scrip Code – 543064

Dear Sir/Madam,

Sub: Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 – Update on USFDA inspection

This is in continuation of our intimation dated August 13, 2025 regarding completion of inspection by the USFDA at our Finished Dosage Formulations Manufacturing Facility (FDF Unit-I) located in Nacharam, Hyderabad, where we have received Form 483 with 6 (six) observations.

In this connection we would like to inform that the Company has now received report from the USFDA, determining the inspection classification of this facility as “Official Action Indicated (OAI)”. The Company is engaging proactively with the USFDA and has initiated a comprehensive remediation program and align the facility fully with global standards. The FDF Unit -1 facility at Nacharam continues to run its operations normally.

Further, as intimated and clarified on September 18, 2025, we reiterate that in FY2025, the US revenue from this formulation unit located at Nacharam contributed less than 2% of the Company’s consolidated revenues and with related EBITDA contribution below 1%. Therefore, it is not expected to have any material impact on the Company’s ongoing operations or supplies.

We remain committed to maintaining the highest standards of quality and regulatory compliance in all our operations and will continue to ensure the manufacture and supply of high-quality pharmaceutical products for global markets.

This is for your information and record.

Thanking you.

Yours faithfully,
For **Cohance Lifesciences Limited**
(Formerly, Suven Pharmaceuticals Limited)

Kundan Kumar Jha
Company Secretary, Compliance Officer and Head-Legal

Cohance Lifesciences Limited
(Formerly, Suven Pharmaceuticals Limited)

Corporate Office: 202, A-Wing, Galaxy Towers, Plot No.1, Hyderabad Knowledge City, TSIC, Raidurg, Hyderabad - 500081, Telangana, India.
Tel: +91 40 2354 9414 / 3311

Registered Office: 215 Atrium, C Wing, 8th Floor, 819-821, Andheri Kurla Road, Chakala, Andheri East, Chakala MIDC, Mumbai - 400093, Maharashtra, India.
Tel: +91 22 6153 9999

CIN: L24299MH2018PLC422236 | Website: www.suvenpharm.com | Company Email: info@suvenpharm.com

